1

Introduction to Pharmaceutical Analysis

This chapter briefly reviews the life of medical products and the manufacture of medical products according to international regulations and guidelines. Based on this review the major areas and usage of pharmaceutical analysis are identified.

1.1 Applications and Definitions

The European Pharmacopeia defines a medical product as:

(a) Any substance or combination of substances presented as having properties for treating or preventing disease in human beings and/or animals; or (b) any substance or combination of substances that may be used in or administered to human beings and/or animals with a view either to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.

A medical product contains a substance that is pharmacologically active and that substance is called the active ingredient (AI) or active pharmaceutical ingredient (API) defined as follows:

Any substance intended to be used in the manufacture of a medicinal product and that, when so used, becomes an active ingredient of the medicinal product. Such substances are intended to furnish a pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure and function of the body.
An herbal medical product is:

*A medicinal product, exclusively containing as active ingredients one or more herbal drugs or one or more herbal drug preparations, or one or more such herbal drugs in combination with one or more such herbal drug preparation.*

Drug substances are administered very rare as the pure active substance. Typically the active substance and excipients (auxiliary substances) are combined into dosage forms to produce the final medical product. An excipient is:

*Any constituent of a medicinal product that is not an active substance.*

Adjuvants, stabilizers, antimicrobial preservatives, diluents, antioxidants, for example, are excipients.

The dosage form can be, for example, a tablet or a capsule or syrup to be administered orally, injections that are for parenteral administration into the body, or ointments for topical administration. Figure 1.1 shows typical dosage forms.

Formulation is the process in which different chemical substances, including the active ingredient and excipients are combined to produce a final medical product. It involves developing a preparation of the drug that is both stable and acceptable to the patient. For orally taken drugs this usually involves incorporating the drug and excipients in a solid

---

**Figure 1.1** Different dosage forms
dosage form such as a tablet or a capsule or a liquid dosage forms such as a syrup. The main function of excipients is summarized as follows:

- Ensure that the preparation has a shape and size that is easy to use for the patient;
- Ensure that the active substance is optimally adsorbed in the patient;
- Ensure that the preparation has an acceptable shelf life;
- Ensure that the preparation does not have an unpleasant taste or odor;
- Ensure easy production.

There is a wide spectrum of different excipients, which varies widely from preparation to preparation. To illustrate this, Table 1.1 shows the excipients of a tablet and syrup which both contain paracetamol as the active ingredient. Paracetamol is both an analgesic \((\text{analgesia} = \text{pain})\) and a antipyretic \((\text{antipyre} = \text{against, pyretos} = \text{fever})\), which means that it is used against pain and fever.

![Table 1.1](image)

<table>
<thead>
<tr>
<th>Content</th>
<th>Amount (mg)</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablet (weight 285 mg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paracetamol</td>
<td>250</td>
<td>Active ingredient</td>
</tr>
<tr>
<td>Hydroxypropyl cellulose</td>
<td></td>
<td>Binder</td>
</tr>
<tr>
<td>Maize starch</td>
<td></td>
<td>Disintegrant</td>
</tr>
<tr>
<td>Talcum</td>
<td></td>
<td>Glidant</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td></td>
<td>Lubricant</td>
</tr>
<tr>
<td>Syrup (volume 1 ml)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paracetamol</td>
<td>24</td>
<td>Active ingredient</td>
</tr>
<tr>
<td>Sorbitol</td>
<td></td>
<td>Sweetener</td>
</tr>
<tr>
<td>Glycerol</td>
<td></td>
<td>Sweetener</td>
</tr>
<tr>
<td>Polyvinylpyrrolidone</td>
<td></td>
<td>Thickening agent</td>
</tr>
<tr>
<td>Saccharine sodium salt</td>
<td></td>
<td>Sweetener</td>
</tr>
<tr>
<td>Methylparabene</td>
<td></td>
<td>Preservative</td>
</tr>
<tr>
<td>Ethylparabene</td>
<td></td>
<td>Preservative</td>
</tr>
<tr>
<td>Propylparabene</td>
<td></td>
<td>Preservative</td>
</tr>
<tr>
<td>Sodium metabisulphite</td>
<td></td>
<td>Antioxidant</td>
</tr>
<tr>
<td>Citric acid</td>
<td></td>
<td>pH regulator</td>
</tr>
<tr>
<td>Sodium citrate</td>
<td></td>
<td>pH regulator</td>
</tr>
<tr>
<td>Strawberry aroma</td>
<td></td>
<td>Flavoring agent</td>
</tr>
<tr>
<td>Water</td>
<td></td>
<td>Solvent</td>
</tr>
</tbody>
</table>

Medical products may be divided into over the counter drugs (OTC), which may be sold directly to the consumer in pharmacies and supermarkets without restrictions, and
prescription only medicine (POM) that must be prescribed by a licensed practitioner. Medical products are predominantly produced by the pharmaceutical companies, only in rare occasions are pharmaceutical products produced in hospitals and in pharmacies. New products are often patented to give the developer exclusive right to produce them. Those that are not patented or with expired patents, are called generic drugs since they can be produced by other companies without restrictions or licenses from the patent holder. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the pharmaceutical industry in Europe employed some 630 000 people, including 110 000 in research and development, in 2009. The trade surplus was Euro 55 200 million, and Euro 26 000 million was spent on pharmaceutical research and development. The retail value of the pharmaceutical market was Euro 215 000 million, which is just under 30% of the world market.

1.2 The Life of Medicines

Figure 1.2 outlines a typical industrial production of a pharmaceutical product. Production starts by ordering the current active ingredient and the necessary starting materials. In some cases, the company produces some of the ingredients, but most commonly they are produced elsewhere by various industrial raw material suppliers. The raw materials arrive in relatively large quantities (1–500 kg) and are typically packed in cardboard drums or in plastic containers. Figure 1.3 shows an example of a received batch of raw material in the photo gallery from a manufacturing facility.

![Diagram of the manufacturing of a medical product](image-url)
Figure 1.4 shows an outline of some areas found in a manufacturing facility. Upon arrival the raw materials are registered in the manufacturer’s documentation system, tagged with internal labels and stored in a separate area of the warehouse or in a separate room where they are in quarantine until they are released for production. Samples of the raw materials are collected and analyzed to ensure that the raw materials are of
satisfactory quality. This is the first of several important areas where pharmaceutical analysis are vital. We focus further on this in Chapter 21. If the results are in accordance with the specifications of the manufacturer the raw materials are labeled as released materials, and transferred to the production facility. Production starts with weighing or measuring the active ingredient and excipients in appropriate amounts for the subsequent production (see Figure 1.3). Then, the raw materials are transferred to the manufacturing machinery. Manufacture of tablets uses several types of equipment such as machinery for granulation, drying and tablet pressing (see Figure 1.3). The manufacture of liquid dosage forms is carried out in large tanks, while the production of ointments and creams are carried in large pots with agitator and heating. When the product leaves the production site samples

Figure 1.3 (Continued)
Figure 1.3  (Continued)
for a comprehensive finished product control is collected. A number of analytical tests are made, and this is another important field of pharmaceutical analysis which is discussed in detail in Chapter 22. The products are in quarantine until the results of the testing show compliance with specifications. The released product is filled in appropriate containers (filling; see Figure 1.3), the containers are marked with labels (labeling; see Figure 1.3) and the containers are packed in cardboard boxes (packaging; see Figure 1.3). Assessment of the finished product embrace all relevant factors, including production conditions, results of in-process testing, a review of manufacturing (including packaging), documentation, compliance with Finished Product Specifications and examination of the final finished pack.

As shown above, the industrial production of pharmaceuticals is a comprehensive process that takes place over many different steps. Typically, production is a batch process, which means that the products are made in limited batches. Each time a batch is produced a new manufacturing process is started from the beginning with new starting materials. Between each production of a given product, the equipment is often used for the production of other products. Consequently the production facility must be cleaned thoroughly between each batch to prevent the material from an earlier production contaminating other products (cross contamination).

After leaving the manufacturer the products are sent to pharmaceutical wholesalers, which provide for their further distribution to pharmacies, hospitals or other retailers where they becomes available to the patients. Medicines have a broad scope of usage, and are used against many types of illness and pain in various parts of the body.

At the start of medication, it is common to follow a standard treatment, but it is well known that different patients may exhibit large variations in response. In such cases it is important to adjust the dosage. One example is the treatment of hypertension. The dosage may be reduced when the blood pressure is too low and the dosage may be increased when the blood pressure is too high. For other types of treatment, such as depression, psychosis and epilepsy, the measurement of effect is difficult; and in those cases therapeutic drug monitoring (TDM) is advised. In TDM blood samples are collected and analyzed to ensure that the drug level is appropriate. The analysis of drugs in biological fluids is called bioanalysis. In addition to TDM, bioanalysis is crucial in drug development programs, in forensic and toxicological analysis and in doping control testing in sports. Bioanalysis is a third major area of pharmaceutical analysis, which is discussed in Chapter 23.

1.3 The Quality of Medical Products

The purchaser of food and drink normally discovers that a product is associated with a significant quality problem if has either an abnormal taste, unusual smell or a look that seems abnormal. Medicines are, however, special. For example, there is no way patients can decide whether a tablet contains the active ingredient, whether it is the correct dosage, or whether any contaminants or degradation products are present. The patient is not in a position to recognize that a medicine is incorrect or defective. The patient literally takes medicines entirely on trust and is at the end of a chain of implicit trust which extends back through administering, dispensing, prescribing and distributing, right back to those
responsible for manufacture of the product. It is therefore mandatory that the pharmaceutical industry maintains the highest standards of quality in the development, manufacture and control of medical products.

Government health authorities are naturally concerned about the quality of medicines, and regulate the development, manufacture and marketing of medical products by a number of laws and guidelines. These are discussed in Chapter 2. The regulations and guidelines are to assure the safety, protection and well being of the consumer or patient. Two important areas are:

- Marketing authorization of medical products;
- Manufacturing authorization of medical products.

Marketing authorization, also called a license, is required before any medicine can be used to treat people. Only when the regulatory bodies are satisfied that the product works as it should, and that it is acceptably safe, is it given a marketing authorization or product license.

The regulatory system also imposes rigorous standards on manufacturers. Manufacturing authorization is required by all pharmaceutical manufacturers and ensures that only authorized manufacturers manufacture all licensed products. Competent authorities regularly inspect the activities of the manufacturers and annually collect samples of marketed medicines for assessment of quality. National Medical Control Agencies have the power to

\[ \text{Figure 1.4 Outline of some areas found in a manufacturing facility} \]
withdraw a product from the market and to suspend production. These Agencies can also
prosecute a manufacturer if the law has been broken.

The holder of a manufacturing authorisation must manufacture medical products so as
to ensure that they are fit for their intended use. The products should comply with the
requirements of the marketing authorization and should not put patients at risk due to
inadequate safety, quality or efficacy. The attainment of quality is the responsibility of the
management, and it relies on a comprehensively designed and correctly implemented
system of Quality Assurance (QA) incorporating Good Manufacturing Practice (GMP) and
Quality Control (QC). The system should be fully documented. The basic concepts of QA,
GMP and QC are inter-related, as shown in Figure 1.5.

Quality Assurance is a wide-ranging concept, which covers all matters that influence
the quality of a product. It is the sum of all organized arrangements that are made to
ensure that medical products are of the quality required for their intended use. Quality
Assurance therefore incorporates GMP, which ensures that products are consistently
produced and controlled to the quality standards appropriate to their intended use and
as required by the Marketing Authorization. The basics of GMP are that all manufacturing
processes are clearly defined, systematically reviewed and shown to be capable of
consistently manufacturing products of the required quality. Quality Control is part of
GMP and is concerned with sampling, specifications and testing, and with the organization,
documentation and release procedures. Release procedures should ensure that the necessary
and relevant tests are actually carried out and that materials are not released for use, nor

---

**Figure 1.5** Illustration of the QA/GMP/QC inter-relationship
products released for sale or supply, until their quality has been judged to be satisfactory. The independence of the Quality Control Department from other departments is considered fundamental. Quality Control is not confined to laboratory operations, but must be involved in all decisions that may concern the quality of a product.

According to European regulations each batch of finished product must be certified by a Qualified Person (QP) before being released for sale or supply.

Before certifying a batch the QP should ensure that at least the following requirements have been met:

- The batch and its manufacture comply with the provisions of the marketing authorization.
- Manufacture has been carried out in accordance with GMP.
- The principal manufacturing and testing processes have been validated (validation is defined as the documented act of demonstrating that processes will consistently lead to the expected results).
- Any deviations or planned changes in production or quality control have been authorized by the persons responsible in accordance with a defined system.
- All the necessary checks and tests have been performed.
- All necessary production and quality control documentation has been completed.
- The QP should in addition take into account any other factors of which he is aware which are relevant for the quality of the batch.

Good documentation constitutes an essential part of the quality assurance system and constitutes a vital part of batch release and certification by the QP. Clearly written documentation and standard operating procedures (SOP) prevent errors from spoken communication and permit tracing of batch history. The documentation include:

- Specifications that in detail describe the requirements that must be fulfilled prior to quality evaluation;
- Manufacturing formulae, processing and packaging instructions;
- Procedures that give directions for performing operations such as cleaning, sampling testing and equipment operation;
- Records providing a history of each batch or product.

The batch documentation shall be retained for at least one year after the expiry date of the batches.

1.4 Summary

Government health authorities have regulated the development, manufacture and marketing of medical products by a number of laws and guidelines to assure the safety, protection and well being of the patient. Market authorization is required before any medical product can be marketed and only authorized manufacturers can produce authorized products. Authorized manufacture is based on a correctly implemented system of Quality Assurance incorporating Good Manufacturing Practice and Quality Control.